Antibiotics (Jun 2022)

Elevated Mortality Risk from CRKp Associated with Comorbidities: Systematic Review and Meta-Analysis

  • Lucas Candido Gonçalves Barbosa,
  • José Arthur Silva e Sousa,
  • Graziela Picciola Bordoni,
  • Gabriel de Oliveira Barbosa,
  • Lilian Carla Carneiro

DOI
https://doi.org/10.3390/antibiotics11070874
Journal volume & issue
Vol. 11, no. 7
p. 874

Abstract

Read online

Carbapenem-resistant Klebsiella pneumoniae has become a public health problem with therapeutic limitations and high mortality associated with comorbidities. Methods: This is a systematic review and meta-analysis with a search in PubMed, SciELO, and Lilacs. Ten articles were selected, considering cohort, case-control, and cross-sectional studies. Tests for proportions and relative risk of mortality were performed, considering a 5% threshold for significance. Statistical analyses were performe dusing Rstudio® software, version 4.0.2 of Ross Ihaka and Robert Genleman in Auckland, New Zealand. Results: Klebsiella pneumoniae, associated with chronic kidney disease, was responsible for 26%/258 deaths, chronic lung disease 28%/169, diabetes 31%/185, liver disease 15%/262, and heart disease 51%/262 deaths. Carbapenem-resistant Klebsiella pneumoniae associated with chronic kidney disease was responsible for 49%/83 deaths, with diabetes 29%/73, and with liver disease 33%/73 deaths. The risk of death from carbapenem-resistant Klebsiella pneumoniae was twice as high as the number of deaths associated with carbapenem-sensitive Klebsiella pneumoniae, RR = 2.07 (p Klebsiella pneumoniae when associated with comorbidities.

Keywords